Value of the CD25+ CD16+ cell determination in defining the prognosis of operable breast cancer patients

R. V. Iaffaioli, G. Frasci, L. Rinaldi, L. Del Vecchio, A. Tortoriello, G. Facchini, V. Perone, V. Montesarchio, C. Vacca, F. Vaia, A. R. Bianco

Research output: Contribution to journalArticlepeer-review

Abstract

The immunologic status of 40 breast cancer patients with operable disease and 50 healthy women was studied at the Division of Medical Oncology of the 2nd Medical School in Naples. Skin tests and lymphocyte subpopulation determination were performed. The same tests were repeated after surgery in the cancer patients. At the same time, the immunologic modifications during chemotherapy (CMF) were studied in a further 25 premenopausal breast cancer patients. The cancer patients did not show significantly different reactivity to recall antigens, nor did surgery or chemotherapy modify this parameter. The breast cancer patients showed a significantly higher CD4+/CD8+ ratio (2.07±1.06 vs. 1.56±0.58; p

Original languageEnglish
Pages (from-to)412-418
Number of pages7
JournalEuropean Journal of Gynaecological Oncology
Volume14
Issue number5
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Value of the CD25+ CD16+ cell determination in defining the prognosis of operable breast cancer patients'. Together they form a unique fingerprint.

Cite this